GLP-1 RAs enhance insulin sensitivity in neurons, counteracting central insulin resistance—an emerging hallmark of Alzheimer’s disease (AD) and Parkinson’s disease (PD) [17,18]. This evidence concerns the gene GCG and early-onset autosomal dominant Alzheimer disease.